Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341837 | 0.92 | ITGB1 (0.38) | MAPK14MAPK13ITGB1ITGA4ALDH1A1 | |
| SCHEMBL1342538 | 0.89 | MYC (0.41) | IDH2 | |
| SCHEMBL1340631 | 0.87 | MAPK14 (0.42) | MAPK14MAPK13IDH2 | |
| SCHEMBL1343648 | 0.86 | FFAR1 (0.43) | FFAR1ITGB1ITGA4PPARG | |
| SCHEMBL1340680 | 0.86 | ITGB1 (0.39) | MAPK14MAPK13ITGB1ITGA4IDH2 | |
| SCHEMBL1342940 | 0.85 | FFAR1 (0.38) | FFAR1MAPK14MAPK13ITGB1ITGA4 | |
| SCHEMBL1342817 | 0.84 | ADRB2 (0.40) | MAPK14MAPK13ITGB1ITGA4TDP1 | |
| SCHEMBL1340565 | 0.83 | NAMPT (0.39) | MAPK14MAPK13 | |
| SCHEMBL2660405 | 0.83 | SMN1; SMN2 (0.39) | MAPK14ALDH1A1L3MBTL1IDH2 | |
| SCHEMBL1343346 | 0.82 | TP53 (0.43) | ITGB1ITGA4TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | FFAR1 1515/4885MAPK14 1028/4885MAPK13 687/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | FFAR1 1515/4885MAPK14 1028/4885MAPK13 687/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | FFAR1 2162/4885MAPK14 1220/4885MAPK13 720/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | FFAR1 1515/4885MAPK14 1028/4885MAPK13 687/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | FFAR1 1515/4885MAPK14 1028/4885MAPK13 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.